<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://molehr.oxfordjournals.org">
<title>Molecular Human Reproduction - recent issues</title>
<link>http://molehr.oxfordjournals.org</link>
<description>Molecular Human Reproduction - RSS feed of recent issues (covers the latest 3 issues, including the current issue) </description>
<prism:eIssn>1460-2407</prism:eIssn>
<prism:publicationName>Molecular Human Reproduction</prism:publicationName>
<prism:issn>1360-9947</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/12/763?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/12/765?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/12/771?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/12/779?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/12/789?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/12/795?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/12/805?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/12/821?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/12/829?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/12/843?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/11/703?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/11/713?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/11/725?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/11/733?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/11/739?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/11/749?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/11/757?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/10/575?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/10/577?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/10/587?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/10/609?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/10/625?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/10/633?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/10/645?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/10/653?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/10/665?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/10/675?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/10/687?rss=1" />
  <rdf:li rdf:resource="http://molehr.oxfordjournals.org/cgi/content/short/15/10/693?rss=1" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/12/763?rss=1">
<title><![CDATA[The ovary: from basic research to clinic]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/12/763?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Hillier, S. G.]]></dc:creator>
<dc:date>Thu, 12 Nov 2009 07:49:48 PST</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap091</dc:identifier>
<dc:title><![CDATA[The ovary: from basic research to clinic]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>763</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>763</prism:startingPage>
<prism:section>Editorial</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/12/765?rss=1">
<title><![CDATA[Disruption of Tsc2 in oocytes leads to overactivation of the entire pool of primordial follicles]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/12/765?rss=1</link>
<description><![CDATA[
<p>To maintain the length of reproductive life in a woman, it is essential that most of her ovarian primordial follicles are maintained in a quiescent state to provide a continuous supply of oocytes. However, our understanding of the molecular mechanisms that control the quiescence and activation of primordial follicles is still in its infancy. In this study, we provide some genetic evidence to show that the tumor suppressor tuberous sclerosis complex 2 (Tsc2), which negatively regulates mammalian target of rapamycin complex 1 (mTORC1), functions in oocytes to maintain the dormancy of primordial follicles. In mutant mice lacking the <I>Tsc2</I> gene in oocytes, the pool of primordial follicles is activated prematurely due to elevated mTORC1 activity in oocytes. This results in depletion of follicles in early adulthood, causing premature ovarian failure (POF). Our results suggest that the Tsc1&ndash;Tsc2 complex mediated suppression of mTORC1 activity is indispensable for maintenance of the dormancy of primordial follicles, thus preserving the follicular pool, and that mTORC1 activity in oocytes promotes follicular activation. Our results also indicate that deregulation of Tsc/mTOR signaling in oocytes may cause pathological conditions of the ovary such as infertility and POF.</p>
]]></description>
<dc:creator><![CDATA[Adhikari, D., Flohr, G., Gorre, N., Shen, Y., Yang, H., Lundin, E., Lan, Z., Gambello, M. J., Liu, K.]]></dc:creator>
<dc:date>Thu, 12 Nov 2009 07:49:49 PST</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap092</dc:identifier>
<dc:title><![CDATA[Disruption of Tsc2 in oocytes leads to overactivation of the entire pool of primordial follicles]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>770</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>765</prism:startingPage>
<prism:section>Original Articles</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/12/771?rss=1">
<title><![CDATA[The forkhead transcription factor FOXL2 is expressed in somatic cells of the human ovary prior to follicle formation]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/12/771?rss=1</link>
<description><![CDATA[
<p>Interactions between germ cells and surrounding somatic cells are central to ovarian development as well as later function. Disruption of these interactions arising from abnormalities in either cell type can lead to premature ovarian failure (POF). The forkhead transcription factor FOXL2 is a candidate POF factor, and mutations in the <I>FOXL2</I> gene are associated with syndromic and non-syndromic ovarian failure. Foxl2-deficient mice display major defects in primordial follicle activation with consequent follicle loss, and earlier roles in gonadal development and sex determination have also been suggested. However, despite its importance no data presently exist on its expression in the developing human ovary. Expression of <I>FOXL2</I> mRNA was demonstrated in the human fetal ovary between 8 and 19 weeks gestation, thus from soon after sex determination to primordial follicle development. Expression in the ovary was higher after 14 weeks than at earlier gestation weeks and was very low in the fetal testis at all ages examined. Immunolocalization revealed FOXL2 expression to be confined to somatic cells, both adjacent to germ cells and those located in the developing ovarian stroma. These cells are the site of action of oocyte-derived activin signalling, but <I>in vitro</I> treatment of human fetal ovaries with activin failed to reveal any regulation of <I>FOXL2</I> transcription by this pathway. In summary, the expression of FOXL2 in somatic cells of the developing human ovary before and during follicle formation supports a conserved and continuing role for this factor in somatic/germ cell interactions from the earliest stages of human ovarian development.</p>
]]></description>
<dc:creator><![CDATA[Duffin, K., Bayne, R.A.L., Childs, A.J., Collins, C., Anderson, R.A.]]></dc:creator>
<dc:date>Thu, 12 Nov 2009 07:49:49 PST</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap065</dc:identifier>
<dc:title><![CDATA[The forkhead transcription factor FOXL2 is expressed in somatic cells of the human ovary prior to follicle formation]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>777</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>771</prism:startingPage>
<prism:section>Original Articles</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/12/779?rss=1">
<title><![CDATA[Stable expression and characterization of N-terminal tagged recombinant human bone morphogenetic protein 15]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/12/779?rss=1</link>
<description><![CDATA[
<p>Oocyte-derived growth factors are critically involved in multiple ovarian processes via paracrine actions. Although recombinant proteins have been applied to dissect the physiological functions of these factors, variation of activities among different protein preparations remains an issue. To further elucidate the roles of one of these growth factors, bone morphogenetic protein 15 (BMP15), in mediating oocyte-regulated molecular and cellular events and to explore its potential clinical application, we engineered the human BMP15 sequence to efficiently produce bioactive recombinant human BMP15 (rhBMP15). The proteolytic cleavage site of the hBMP15 precursor was optimized to facilitate the production of the mature protein, and a FLAG-tag was placed at the N-terminus of the mature region to ease purification and avoid potential interference of the tag with the cystine knot structure. The rhBMP15 protein was purified using anti-FLAG M2 affinity gel. Our results demonstrated that the N-terminal tagged rhBMP15 was efficiently processed in HEK-293 cells. Furthermore, the purified rhBMP15 could activate SMAD1/5/8 and induce the transcription of genes encoding cumulus expansion-related transcripts (<I>Ptx3, Has2, Tnfaip6</I> and <I>Ptgs2</I>), inhibitory SMADs (<I>Smad6</I> and <I>Smad7</I>), BMP antagonists (<I>Grem1</I> and <I>Fst</I>), activin/inhibin <I>&beta;</I>A (<I>Inhba</I>) and <I>&beta;</I>B (<I>Inhbb</I>) subunits, etc. Thus, our rhBMP15 containing a genetically modified cleavage sequence and an N-terminal FLAG-tag can be efficiently produced, processed and secreted in a mammalian expression system. The purified rhBMP15 is also biologically active and very stable, and can induce the expression of a variety of mouse granulosa cell genes.</p>
]]></description>
<dc:creator><![CDATA[Li, Q., Rajanahally, S., Edson, M. A., Matzuk, M. M.]]></dc:creator>
<dc:date>Thu, 12 Nov 2009 07:49:49 PST</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap062</dc:identifier>
<dc:title><![CDATA[Stable expression and characterization of N-terminal tagged recombinant human bone morphogenetic protein 15]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>788</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>779</prism:startingPage>
<prism:section>Original Articles</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/12/789?rss=1">
<title><![CDATA[Oocyte peptides as paracrine tools for ovarian stimulation and oocyte maturation]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/12/789?rss=1</link>
<description><![CDATA[
<p>Recent studies report the production and isolation of a stable bioactive recombinant human bone morphogenetic protein 15 (rhBMP15) that is appropriately processed in HEK-293 cells and activates the SMAD 1/5/8 pathway in mouse granulosa cell cultures. Further, the purified rhBMP15 induces the expression of genes associated with cumulus expansion. Thanks to recent research, we have a greater understanding of the importance of the dialogue that occurs between the oocyte and the granulosa cell layer with regard to regulating folliculogenesis and the acquisition of oocyte developmental competence and maturation. BMP15 is one of the critical components of these intra-follicular communication pathways. The production of recombinant human BMP15 is important for understanding the biochemistry of this specific pathway and for also fully understanding its functional contributions to mediating oocyte development. The production of a stable recombinant human BMP15 is also important for use in experiments aimed at optimizing ovarian stimulation protocols and <I>in vitro</I> oocyte maturation methods. This is required to improve oocyte and embryonic developmental competence and increase our ability to effectively use <I>in vitro</I> methods for animal production and the treatment of human infertility.</p>
]]></description>
<dc:creator><![CDATA[Mottershead, D. G., Watson, A. J.]]></dc:creator>
<dc:date>Thu, 12 Nov 2009 07:49:49 PST</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap085</dc:identifier>
<dc:title><![CDATA[Oocyte peptides as paracrine tools for ovarian stimulation and oocyte maturation]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>794</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>789</prism:startingPage>
<prism:section>Commentary</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/12/795?rss=1">
<title><![CDATA[The primordial pool of follicles and nest breakdown in mammalian ovaries]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/12/795?rss=1</link>
<description><![CDATA[
<p>The creation of the pool of follicles available for selection and ovulation is a multi-faceted, tightly regulated process that spans the period from embryonic development through to the first reproductive cycle of the organism. In mice, this development can occur in mere weeks, but in humans, it is sustained for years. Embryonic germ cell development involves the migration of primordial germs cells to the genital ridge, and the mitotic division of germ cell nuclei without complete cytokinesis to form a multi-nucleated syncytia, or germ cell nest. Through combined actions of germ cell apoptosis and somatic cell migration, the germ cell nuclei are packaged, with surrounding granulosa cells, into primordial follicles to form the initial follicle pool. Though often dismissed as quiescent and possibly uninteresting, this initial follicle pool is actually quite dynamic. In a very strictly controlled mechanism, a large portion of the initial primordial follicles formed is lost by atresia before cycling even begins. Remaining follicles can undergo alternate fates of continued dormancy or selection leading to follicular growth and differentiation. Together, the processes involved in the fate decisions of atresia, sustained dormancy, or activation carve out the follicle pool of puberty, the pool of available oocytes from which all future reproductive cycles of the female can choose. The formation of the initial and pubertal follicle pools can be predictably affected by exogenous treatment with hormones or molecules such as activin, demonstrating the ways the ovary controls the quality and quantity of germ cells maintained. Here, we review the biological processes involved in the formation of the initial follicle pool and the follicle pool of puberty, address the alternate models for regulating germ cell number and outline how the ovary quality-controls the germ cells produced.</p>
]]></description>
<dc:creator><![CDATA[Tingen, C., Kim, A., Woodruff, T. K.]]></dc:creator>
<dc:date>Thu, 12 Nov 2009 07:49:49 PST</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap073</dc:identifier>
<dc:title><![CDATA[The primordial pool of follicles and nest breakdown in mammalian ovaries]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>803</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>795</prism:startingPage>
<prism:section>New Research Horizon Reviews</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/12/805?rss=1">
<title><![CDATA[Oogenesis and cell death in human prenatal ovaries: what are the criteria for oocyte selection?]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/12/805?rss=1</link>
<description><![CDATA[
<p>Prenatal oogenesis produces hundreds of thousands of oocytes, most of which are discarded through apoptosis before birth. Despite this large-scale selection, the survivors do not constitute a perfect population, and the factors at the cellular level that result in apoptosis or survival of any individual oocyte are largely unknown. What then are the selection criteria that determine the size and quality of the ovarian reserve in women? This review focuses on new data at the cellular level, on human prenatal oogenesis, offering clues about the importance of the timing of entry to meiotic prophase I by linking the stages and progress through MPI with the presence or absence of apoptotic markers. The characteristics and responsiveness of cultured human fetal ovarian tissue at different gestational ages to growth factor supplementation and the impact of meiotic abnormalities upon apoptotic markers are discussed. Future work will require the use of a tissue culture model of prenatal oogenesis in order to investigate the fate of individual live oocytes at different stages of development.</p>
]]></description>
<dc:creator><![CDATA[Hartshorne, G.M., Lyrakou, S., Hamoda, H., Oloto, E., Ghafari, F.]]></dc:creator>
<dc:date>Thu, 12 Nov 2009 07:49:49 PST</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap055</dc:identifier>
<dc:title><![CDATA[Oogenesis and cell death in human prenatal ovaries: what are the criteria for oocyte selection?]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>819</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>805</prism:startingPage>
<prism:section>New Research Horizon Reviews</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/12/821?rss=1">
<title><![CDATA[Control of ovulation in mice by progesterone receptor-regulated gene networks]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/12/821?rss=1</link>
<description><![CDATA[
<p>The mid-cycle surge of luteinizing hormone (LH) induces ovulation, a process during which a fertilizable oocyte is released from a mature ovarian follicle. Although ovulation is a physiologically well-characterized event, the underlying molecular pathways remain poorly understood. Progesterone receptor (PGR), which mediates the biological effects of the steroid hormone progesterone, has emerged as a key regulator of ovulation in mice. The development of a progesterone-receptor-null (<I>Pgr</I>-null) mouse model confirmed a critical role of this hormone in ovulation because in these mutant mice, mature pre-ovulatory follicles fail to release the oocytes. This animal model has thus presented a unique opportunity to study the molecular pathways underlying ovulation. Gene-expression profiling experiments by several groups, using the ovaries of <I>Pgr</I>-null mice, revealed novel gene networks, which act downstream of PGR to control ovulation. These genes encode diverse molecules such as proteases, transcription factors, cell-adhesion molecules, modulators of vascular activities and regulators of inflammation. Functional analyses using gene-knockout mouse models have confirmed that some of these factors play critical roles during ovulation. The knowledge gained from these studies has helped us to understand better the molecular mechanisms that facilitate the release of oocytes from pre-ovulatory follicles. Further analysis of the role of molecular regulators of ovulation will help identify useful molecular targets that would allow the development of improved contraceptives and new therapeutics for anovulatory infertility.</p>
]]></description>
<dc:creator><![CDATA[Kim, J., Bagchi, I. C., Bagchi, M. K.]]></dc:creator>
<dc:date>Thu, 12 Nov 2009 07:49:49 PST</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap082</dc:identifier>
<dc:title><![CDATA[Control of ovulation in mice by progesterone receptor-regulated gene networks]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>828</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>821</prism:startingPage>
<prism:section>New Research Horizon Reviews</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/12/829?rss=1">
<title><![CDATA[Genetic and gene expression analyses of the polycystic ovary syndrome candidate gene fibrillin-3 and other fibrillin family members in human ovaries]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/12/829?rss=1</link>
<description><![CDATA[
<p>Several studies have demonstrated an association between polycystic ovary syndrome (PCOS) and the dinucleotide repeat microsatellite marker D19S884, which is located in intron 55 of the fibrillin-3 (<I>FBN3</I>) gene. Fibrillins, including FBN1 and 2, interact with latent transforming growth factor (TGF)-&beta;-binding proteins (LTBP) and thereby control the bioactivity of TGF&beta;s. TGF&beta;s stimulate fibroblast replication and collagen production. The PCOS ovarian phenotype includes increased stromal collagen and expansion of the ovarian cortex, features feasibly influenced by abnormal fibrillin expression. To examine a possible role of fibrillins in PCOS, particularly FBN3, we undertook tagging and functional single nucleotide polymorphism (SNP) analysis (32 SNPs including 10 that generate non-synonymous amino acid changes) using DNA from 173 PCOS patients and 194 controls. No SNP showed a significant association with PCOS and alleles of most SNPs showed almost identical population frequencies between PCOS and control subjects. No significant differences were observed for microsatellite D19S884. In human PCO stroma/cortex (<I>n</I> = 4) and non-PCO ovarian stroma (<I>n</I> = 9), follicles (<I>n</I> = 3) and corpora lutea (<I>n</I> = 3) and in human ovarian cancer cell lines (KGN, SKOV-3, OVCAR-3, OVCAR-5), <I>FBN1</I> mRNA levels were approximately 100 times greater than <I>FBN2</I> and 200&ndash;1000-fold greater than <I>FBN3</I>. Expression of <I>LTBP-1</I> mRNA was 3-fold greater than <I>LTBP-2</I>. We conclude that <I>FBN3</I> appears to have little involvement in PCOS but cannot rule out that other markers in the region of chromosome 19p13.2 are associated with PCOS or that <I>FBN3</I> expression occurs in other organs and that this may be influencing the PCOS phenotype.</p>
]]></description>
<dc:creator><![CDATA[Prodoehl, M. J., Hatzirodos, N., Irving-Rodgers, H. F., Zhao, Z. Z., Painter, J. N., Hickey, T. E., Gibson, M. A., Rainey, W. E., Carr, B. R., Mason, H. D., Norman, R. J., Montgomery, G. W., Rodgers, R. J.]]></dc:creator>
<dc:date>Thu, 12 Nov 2009 07:49:49 PST</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap072</dc:identifier>
<dc:title><![CDATA[Genetic and gene expression analyses of the polycystic ovary syndrome candidate gene fibrillin-3 and other fibrillin family members in human ovaries]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>841</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>829</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/12/843?rss=1">
<title><![CDATA[Paracrine support of ovarian stimulation]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/12/843?rss=1</link>
<description><![CDATA[
<p>Assisted reproductive technology has evolved on the back of blunderbuss ovarian stimulation regimes designed to maximize the number of oocytes recoverable for treatment purposes. However, oocyte &lsquo;quality&rsquo; is finely programmed by local paracrine and autocrine signalling events during folliculogenesis and can be adversely affected by inappropriate gonadotrophic stimulation. This brief review traces the full follicular lifespan&mdash;from initiation to ovulation&mdash;to identify gonadotrophin-responsive checkpoints likely to impact oocyte quality. It is argued that these might be targeted during controlled ovarian stimulation therapy to (i) increase responsiveness to FSH through follicular priming with LH or hCG, (ii) improve follicular synchrony and oocyte quality through conditioning with FSH and (iii) promote &lsquo;gold standard&rsquo; pre-ovulatory maturation through follicular coasting with LH or hCG. It is concluded that whereas there can be no one-size-fits-all approach to ovarian stimulation, treatment regimes based on paracrine principles and tailored to personal needs will always be more likely to achieve the desired outcome.</p>
]]></description>
<dc:creator><![CDATA[Hillier, S. G.]]></dc:creator>
<dc:date>Thu, 12 Nov 2009 07:49:49 PST</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap086</dc:identifier>
<dc:title><![CDATA[Paracrine support of ovarian stimulation]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>850</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>843</prism:startingPage>
<prism:section>New Research Horizon Reviews</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/11/703?rss=1">
<title><![CDATA[Recent progress in luteinizing hormone/human chorionic gonadotrophin hormone research]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/11/703?rss=1</link>
<description><![CDATA[
<p>The role of luteinizing hormone (LH) and human chorionic gonadotrophin hormone (hCG) in the regulation of normal reproductive functions in males and females is quite well established. Besides the use of hCG in the development of diagnostic immunoassays, it has been successfully used in the induction of final follicular maturation and ovulation in the assisted reproductive technologies. The basic and clinical research on the nongonadal actions of LH/hCG in the recent years has extended the potential of using these hormones in several clinical indications. Hereby we will analyze the advances in the LH/hCG research (briefly emphasizing the nongonadal research), which has the potential for multiple novel therapies in reproductive and the other areas of medicine.</p>
]]></description>
<dc:creator><![CDATA[Rahman, N. A., Rao, C.V.]]></dc:creator>
<dc:date>Thu, 15 Oct 2009 08:42:52 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap067</dc:identifier>
<dc:title><![CDATA[Recent progress in luteinizing hormone/human chorionic gonadotrophin hormone research]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>711</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>703</prism:startingPage>
<prism:section>New Research Horizon Reviews</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/11/713?rss=1">
<title><![CDATA[Leukocytes are primed in peripheral blood for activation during term and preterm labour]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/11/713?rss=1</link>
<description><![CDATA[
<p>We hypothesized that the priming and activation of maternal leukocytes in peripheral blood is a key component of parturition, and that inappropriate preterm priming of leukocytes might initiate preterm labour and delivery. The purpose of this study was to characterize peripheral blood leukocyte activation during human term and preterm labour. We obtained blood samples from pregnant women at term and preterm, both in labour and not in labour. Leukocytes were characterized according to cell subtype and cell surface marker expression. Additionally, we quantified leukocyte cytokine mRNA production, migratory ability and reactive oxygen species production of neutrophils and macrophages. We found that both term and preterm labour were associated with an increase in monocyte and neutrophil proportion or number&mdash;neutrophil migratory ability and cell surface marker expression indicating activation. Messenger RNA expression of IL-1&beta; and IL-8, MCP-1 and TLR-2 was also increased. We conclude that leukocytes in peripheral blood are primed in preparation for activation during term and preterm labour, and that this may contribute to the pathophysiological events of parturition. These data may lead to novel therapies and diagnostic tools for the prevention and/or diagnosis of preterm birth.</p>
]]></description>
<dc:creator><![CDATA[Yuan, M., Jordan, F., McInnes, I.B., Harnett, M.M., Norman, J.E.]]></dc:creator>
<dc:date>Thu, 15 Oct 2009 08:42:52 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap054</dc:identifier>
<dc:title><![CDATA[Leukocytes are primed in peripheral blood for activation during term and preterm labour]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>724</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>713</prism:startingPage>
<prism:section>Original Research</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/11/725?rss=1">
<title><![CDATA[Metastasis associated lung adenocarcinoma transcript 1 is up-regulated in placenta previa increta/percreta and strongly associated with trophoblast-like cell invasion in vitro]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/11/725?rss=1</link>
<description><![CDATA[
<p>Placenta previa increta/percreta (I/P) is a severe form of invasive placentation associated with massive peripartum hemorrhage, which often requires Cesarean hysterectomy. The pathogenesis of invasive placentation is multidimensional, involving decidual deficiency, endomyometrial damage and excessively deep trophoblast invasion into the uterus. In this study, annealing control primer&ndash;polymerase chain reaction (ACP&ndash;PCR) was used to identify differentially expressed genes, which may impair placentation resulting in placenta previa I/P. Placental tissues from I/P and non-increta/percreta (non-I/P) sites were concomitantly collected from patients undergoing Cesarean hysterectomy. After ACP&ndash;PCR experiments (three patients), the differentially expressed bands, consistently showing up- or down-regulated trends between each of the I/P and non-I/P tissue pairs, were cloned and sequenced. Human non-protein coding metastasis associated lung adenocarcinoma transcript 1 (MALAT-1) gene was identified. Real-time quantitative PCR (10 patients) confirmed significant overexpression of MALAT-1 in I/P samples (<I>P</I> = 0.005). To investigate the role of MALAT-1 gene in the regulation of trophoblast cell invasion, targeting of MALAT-1 mRNA expression with short interfering RNA (siRNA) in trophoblast-like BeWo, JAR and JEG-3 choriocarcinoma cells was performed. The invasion ability of these cells was significantly suppressed after siRNA silencing (<I>P</I> &lt; 0.001), and this was not correlated with abnormal MMP-2 and MMP-9 enzyme activities. Our results suggest that MALAT-1 expression in placenta previa I/P is increased and its down-regulation inhibits trophoblast-like cell invasion <I>in vitro</I>. MALAT-1 might be involved in regulating trophoblast invasion during the development of advanced invasive placentation.</p>
]]></description>
<dc:creator><![CDATA[Tseng, J.-J., Hsieh, Y.-T., Hsu, S.-L., Chou, M.-M.]]></dc:creator>
<dc:date>Thu, 15 Oct 2009 08:42:52 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap071</dc:identifier>
<dc:title><![CDATA[Metastasis associated lung adenocarcinoma transcript 1 is up-regulated in placenta previa increta/percreta and strongly associated with trophoblast-like cell invasion in vitro]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>731</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>725</prism:startingPage>
<prism:section>Original Research</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/11/733?rss=1">
<title><![CDATA[Mutations in the protamine locus: association with spermatogenic failure?]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/11/733?rss=1</link>
<description><![CDATA[
<p>The protamine locus consists of a 28.5 kb region with a linear array of the protamine (<I>PRM)1</I>, <I>PRM2</I>, <I>PRM3</I> and transition nuclear protein (<I>TNP)2</I> genes. Several studies indicate an abnormal expression pattern of protamine genes associated with male infertility, although the molecular mechanism underlying this observation is unclear. Here, we determined the spectrum of DNA variants present in all four genes in men with unexplained infertility compared with an ancestry-matched fertile/normospermic population. A total of 160 control individuals and at least 125 infertile men with either idiopathic azoospermia or oligozoospermia were sequenced for the open reading frame of <I>PRM1</I>, <I>PRM2, PRM3</I> and <I>TNP2</I> genes. All individuals carried an apparently intact Y chromosome. Of the 28 variants identified, 21 were previously described in the literature. The novel variants that were observed only in the infertile cohort included the SNP c.65G&gt;A mutation which resulted in an amino acid change at the codon 22 (p.Ser22Asn) in the <I>PRM1</I> gene, a mutation in the promoter region of <I>PRM2</I> (&ndash;67C&gt;T) and a nonsense mutation in the <I>PRM3</I> gene. These data are consistent with that of previous studies which have indicated that mutations in the protamine locus may be an infrequent cause of male infertility.</p>
]]></description>
<dc:creator><![CDATA[Imken, L., Rouba, H., El Houate, B., Louanjli, N., Barakat, A., Chafik, A., McElreavey, K.]]></dc:creator>
<dc:date>Thu, 15 Oct 2009 08:42:52 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap056</dc:identifier>
<dc:title><![CDATA[Mutations in the protamine locus: association with spermatogenic failure?]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>738</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>733</prism:startingPage>
<prism:section>Original Research</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/11/739?rss=1">
<title><![CDATA[Evaluation of genome coverage and fidelity of multiple displacement amplification from single cells by SNP array]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/11/739?rss=1</link>
<description><![CDATA[
<p>The scarce amount of DNA contained in a singe cell is a limiting factor for clinical application of preimplantation genetic diagnosis mainly due to the risk of misdiagnosis caused by allele dropout and the difficulty in obtaining copy number variations in all 23 pairs of chromosomes. Multiple displacement amplification (MDA) has been reported to generate large quantity of products from small amount of templates. Here, we evaluated the fidelity of whole-genome amplification MDA from single or a few cells and determined the accuracy of chromosome copy number assessment on these MDA products using an Affymetrix 10K 2.0 SNP Mapping Array. An average coverage rate (86.2%) from single cells was obtained and the rates increased significantly when five or more cells were used as templates. Higher concordance for chromosome copy number from single cells could be achieved when the MDA amplified product was used as reference (93.1%) than when gDNA used as reference (82.8%). The present study indicates that satisfactory genome coverage can be obtained from single-cell MDA which may be used for studies where only a minute amount of genetic materials is available. Clinically, MDA coupled with SNP mapping array may provide a reliable and accurate method for chromosome copy number analysis and most likely for the detection of single-gene disorders as well.</p>
]]></description>
<dc:creator><![CDATA[Ling, J., Zhuang, G., Tazon-Vega, B., Zhang, C., Cao, B., Rosenwaks, Z., Xu, K.]]></dc:creator>
<dc:date>Thu, 15 Oct 2009 08:42:53 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap066</dc:identifier>
<dc:title><![CDATA[Evaluation of genome coverage and fidelity of multiple displacement amplification from single cells by SNP array]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>747</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>739</prism:startingPage>
<prism:section>Original Research</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/11/749?rss=1">
<title><![CDATA[Regulation of soluble vascular endothelial growth factor receptor 1 secretion from human endothelial cells by tissue inhibitor of metalloproteinase 1]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/11/749?rss=1</link>
<description><![CDATA[
<p>Vascular endothelial growth factor (VEGF) and its soluble receptor (sVEGFR-1) are key regulators in human ovarian angiogenesis. Produced by granulosa and ovarian theca interna cells, VEGF promotes blood vessel growth during follicular development and corpus luteum formation, whereas sVEGFR-1, which is secreted by endothelial cells, functions as an antagonist to VEGF activity by binding it. In order to gain further insights into the regulatory mechanisms of ovarian angiogenesis, the aim of the present study was to analyze the influence of tissue inhibitor of metalloproteinase 1 (TIMP-1), which is actively involved in the degradation and remodeling of the extracellular matrix, on sVEGFR-1 secretion of cultured human umbilical vein endothelial cells. sVEGFR-1 production was determined in the culture supernatant by Sandwich-ELISA. We showed that TIMP-1 produced by human granulosa cells and recombinant human TIMP-1 both significantly increased the production of sVEGFR-1 in endothelial cells. Also, the down-regulation of TIMP-1 expression by RNA interference resulted in a significant reduction of endothelial sVEGFR-1 secretion into the culture medium. Furthermore, TIMP-1 weakly inhibited proliferation of VEGF-stimulated endothelial cells. In conclusion, our results provide evidence that TIMP-1 increases the production of sVEGFR-1 in endothelial cells and thus may reduce VEGF bioavailability, leading to reduced blood vessel growth in the ovary.</p>
]]></description>
<dc:creator><![CDATA[Bruegmann, E., Gruemmer, R., Neulen, J., Motejlek, K.]]></dc:creator>
<dc:date>Thu, 15 Oct 2009 08:42:53 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap053</dc:identifier>
<dc:title><![CDATA[Regulation of soluble vascular endothelial growth factor receptor 1 secretion from human endothelial cells by tissue inhibitor of metalloproteinase 1]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>756</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>749</prism:startingPage>
<prism:section>Original Research</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/11/757?rss=1">
<title><![CDATA[An RNA spiking method demonstrates that 18S rRNA is regulated by progesterone in the mouse uterus]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/11/757?rss=1</link>
<description><![CDATA[
<p>Identifying suitable housekeeping genes for quantitative RT&ndash;PCR in the uterus is problematic, as this tissue undergoes significant structural and functional alterations during the oestrous cycle and pregnancy in response to circulating hormones. The suitability of 18S rRNA as a housekeeping gene in mouse uterus was investigated by introducing an &lsquo;RNA spike&rsquo; standard into the reverse transcription reaction. 18S rRNA levels increased by Day 4 of pregnancy and after progesterone administration in ovariectomized mice. We conclude that 18S rRNA is not a suitable housekeeping gene for quantitative RT&ndash;PCR analysis in progesterone-responsive tissues, and the RNA spiking method provides a suitable alternative.</p>
]]></description>
<dc:creator><![CDATA[Craythorn, R.G., Girling, J.E., Hedger, M.P., Rogers, P.A.W., Winnall, W.R.]]></dc:creator>
<dc:date>Thu, 15 Oct 2009 08:42:53 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap058</dc:identifier>
<dc:title><![CDATA[An RNA spiking method demonstrates that 18S rRNA is regulated by progesterone in the mouse uterus]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>761</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>757</prism:startingPage>
<prism:section>Technical Note</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/10/575?rss=1">
<title><![CDATA[Endometriosis: science and sense]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/10/575?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Winterhager, E., Fazleabas, A., Hillier, S.]]></dc:creator>
<dc:date>Tue, 15 Sep 2009 08:16:32 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap074</dc:identifier>
<dc:title><![CDATA[Endometriosis: science and sense]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>575</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>575</prism:startingPage>
<prism:section>Editorial</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/10/577?rss=1">
<title><![CDATA[The non-human primate model of endometriosis: research and implications for fecundity]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/10/577?rss=1</link>
<description><![CDATA[
<p>The development of an animal model of endometriosis is crucial for the investigation of disease pathogenesis and therapeutic intervention. These models will enhance our ability to evaluate the causes for the subfertility associated with disease and provide a first-line validation of treatment modulators. Currently rodents and non-human primate models have been developed, but each model has their limitations. The aim of this manuscript is to summarize the current findings and theories on the development of endometriosis and disease progression and the effectiveness of therapeutic targets using the experimental induced model of endometriosis in the baboon (<I>Papio anubis</I>).</p>
]]></description>
<dc:creator><![CDATA[Braundmeier, A.G., Fazleabas, A.T.]]></dc:creator>
<dc:date>Tue, 15 Sep 2009 08:16:32 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap057</dc:identifier>
<dc:title><![CDATA[The non-human primate model of endometriosis: research and implications for fecundity]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>586</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>577</prism:startingPage>
<prism:section>New Research Horizon Reviews</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/10/587?rss=1">
<title><![CDATA[Epigenetics of endometriosis]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/10/587?rss=1</link>
<description><![CDATA[
<p>Endometriosis is a common gynecologic disorder with an enigmatic etiopathogenesis. Although it has been proposed that endometriosis is a hormonal disease, an autoimmune disease, a genetic disease, and a disease caused by exposure to environmental toxins, our understanding of its etiopathogenesis is still inadequate, as reflected by recent apparent setbacks in clinical trials on endometriosis. In the last 5 years, evidence has emerged that endometriosis may be an epigenetic disease. In this article, the evidence in support of this hypothesis is reviewed, and its diagnostic, therapeutic and prognostic implications discussed. Publications, up to the end of June 2009, pertaining to epigenetic aberration in endometriosis were identified through PubMed. In addition, publications on related studies were also retrieved and reviewed. Epigenetics appears to be a common denominator for hormonal and immunological aberrations in endometriosis. Epigenetics also appears to have a better explanatory power than genetics. There is accumulating evidence that various epigenetic aberrations exist in endometriosis. <I>In vitro</I> studies show that histone deacetylase inhibitors may be promising therapeutics for treating endometriosis. In conclusion, several lines of evidence suggest that epigenetics plays a definite role in the pathogenesis and pathophysiology of endometriosis. As such, endometriosis is possibly treatable by rectifying epigenetic aberrations through pharmacological means. DNA methylation markers may also be useful for diagnostic and prognostic purposes. It is also possible that the delineation of the epigenetic changes accompanied by the genesis and progression of endometriosis could lead to interventions that reduce the risk of developing endometriosis.</p>
]]></description>
<dc:creator><![CDATA[Guo, S.-W.]]></dc:creator>
<dc:date>Tue, 15 Sep 2009 08:16:32 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap064</dc:identifier>
<dc:title><![CDATA[Epigenetics of endometriosis]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>607</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>587</prism:startingPage>
<prism:section>New Research Horizon Reviews</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/10/609?rss=1">
<title><![CDATA[Reassessing the evidence for the link between dioxin and endometriosis: from molecular biology to clinical epidemiology]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/10/609?rss=1</link>
<description><![CDATA[
<p>A 1993 study reporting the link between exposure to dioxin and the risk of developing endometriosis in rhesus monkeys prompted many investigators to look suspiciously at dioxin. Since 1993, many <I>in vitro</I>, animal and epidemiological studies have been published, but the link between dioxin exposure and endometriosis is still unclear. The aim of our review is to present a summary of the biological effects of dioxin and its aryl hydrocarbon receptor, and to reassess the evidence presented in published, <I>in vitro</I>, preclinical and epidemiological studies regarding the association between dioxins and endometriosis. Although <I>in vitro</I> and animal studies provide results in support for a role of dioxins in the pathogenesis of endometriosis, caution should be exercised since these findings are mostly context dependent and since negative findings from these studies are rarely published. On the basis of our review of original epidemiological studies, no significant evidence can be found to support a link between dioxins and endometriosis in women. This observation can be explained by positive publication bias and by significant methodological problems associated with these studies, or by the absence of such a link. In conclusion, it seems that there is insufficient evidence at this moment in support of the hypothesis that dioxin exposure may lead to increased risk of developing endometriosis in women.</p>
]]></description>
<dc:creator><![CDATA[Guo, S.-W., Simsa, P., Kyama, C. M., Mihalyi, A., Fulop, V., Othman, E.-E. R., D'Hooghe, T. M.]]></dc:creator>
<dc:date>Tue, 15 Sep 2009 08:16:32 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap075</dc:identifier>
<dc:title><![CDATA[Reassessing the evidence for the link between dioxin and endometriosis: from molecular biology to clinical epidemiology]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>624</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>609</prism:startingPage>
<prism:section>New Research Horizon Reviews</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/10/625?rss=1">
<title><![CDATA[MicroRNA expression profiling of eutopic secretory endometrium in women with versus without endometriosis]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/10/625?rss=1</link>
<description><![CDATA[
<p>Endometriosis is a common gynecologic disorder characterized by pain and infertility. In addition to estrogen dependence, progesterone resistance is an emerging feature of this disorder. Specifically, a delayed transition from the proliferative to secretory phase as evidenced by dysregulation of progesterone target genes and maintenance of a proliferative molecular fingerprint in the early secretory endometrium (ESE) has been reported. MicroRNAs (miRNAs) are small noncoding RNAs that collectively represent a novel class of regulators of gene expression. In an effort to investigate further the observed progesterone resistance in the ESE of women with endometriosis, we conducted array-based, global miRNA profiling. We report distinct miRNA expression profiles in the ESE of women with versus without endometriosis in a subset of samples previously used in global gene expression analysis. Specifically, the miR-9 and miR-34 miRNA families evidenced dysregulation. Integration of the miRNA and gene expression profiles provides unique insights into the molecular basis of this enigmatic disorder and, possibly, the regulation of the proliferative phenotype during the early secretory phase of the menstrual cycle in affected women.</p>
]]></description>
<dc:creator><![CDATA[Burney, R.O., Hamilton, A.E., Aghajanova, L., Vo, K.C., Nezhat, C.N., Lessey, B.A., Giudice, L.C.]]></dc:creator>
<dc:date>Tue, 15 Sep 2009 08:16:32 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap068</dc:identifier>
<dc:title><![CDATA[MicroRNA expression profiling of eutopic secretory endometrium in women with versus without endometriosis]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>631</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>625</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/10/633?rss=1">
<title><![CDATA[Progestins inhibit expression of MMPs and of angiogenic factors in human ectopic endometrial lesions in a mouse model]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/10/633?rss=1</link>
<description><![CDATA[
<p>Progestins are successfully used in the treatment of endometriosis; however, the exact mechanisms of their action are still unsolved. We here focused on the effect of different progestins on parameters of extracellular matrix degradation and angiogenesis involved in the establishment and maintenance of ectopic endometrial lesions. Human endometrium was intraperitoneally transplanted into nude mice. After 7 and 28 days of treatment with progesterone, dydrogesterone, or its metabolite dihydrodydrogesterone, respectively, ectopic lesions were evaluated for proliferation and apoptosis. Expression of estrogen receptor , progesterone receptor-AB, the angiogenetic factors, cysteine-rich angiogenic inducer (CYR61), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGFA) and the matrix metalloproteinase (MMP)-2, -3, -7 and -9 was investigated. Functional impact on angiogenesis was evaluated by density of microvessels and of vessels stabilized by pericytes within the ectopic lesions. Although dydrogesterone significantly reduced proliferation of endometrial stromal cells after 28 days, suppression of apoptosis was independent from progestins. Expression of MMP-2 was significantly reduced by all progestins and MMP-3 by dydrogesterone. In the grafted endometrial tissue, transcription of bFGF was suppressed by progesterone and dihydrodydrogesterone, and VEGFA and CYR61 by dihydrodydrogesterone and dydrogesterone. In parallel, microvessel density was slightly suppressed by progestins, whereas number of stabilized vessels increased. Thus, progestins regulate factors important for the establishment and maintenance of ectopic endometrial lesions.</p>
]]></description>
<dc:creator><![CDATA[Monckedieck, V., Sannecke, C., Husen, B., Kumbartski, M., Kimmig, R., Totsch, M., Winterhager, E., Grummer, R.]]></dc:creator>
<dc:date>Tue, 15 Sep 2009 08:16:32 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap063</dc:identifier>
<dc:title><![CDATA[Progestins inhibit expression of MMPs and of angiogenic factors in human ectopic endometrial lesions in a mouse model]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>643</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>633</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/10/645?rss=1">
<title><![CDATA[Connexin expression pattern in the endometrium of baboons is influenced by hormonal changes and the presence of endometriotic lesions]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/10/645?rss=1</link>
<description><![CDATA[
<p>Experimentally induced endometriosis in baboons serves as an elegant model to discriminate between endometrial genes which are primarily associated with normal endometrial function and those that are changed by the presence of endometriotic lesions. Since connexin genes are characteristic of the hormonally regulated differentiation of the endometrium, we have examined connexin expression in baboon endometrium to delineate if they are altered in response to the presence of endometriotic lesions. Connexin expression in the endometrium of cycling baboons is similar to that of the human endometrium with Connexin(Cx)43 being primarily seen in the stromal compartment and Cx26 and Cx32 being present predominantly in the epithelium. Although Cx32 is up-regulated during the secretory phase, Cx26 and Cx43 are down-regulated. In the baboon model of induced endometriosis a change in connexin pattern was evident in the presence of endometriotic lesions. In the secretory phase, Cx26 and Cx32 are no longer present in the epithelium but Cx26 is now observed primarily in the stromal cells. Infusion of chorionic gonadotrophin in a manner that mimics blastocyst transit <I>in utero</I> failed to rescue the aberrant stromal expression of Cx26 that is associated with the presence of endometriotic lesions suggesting an impairment of the implantation process. The altered connexin pattern coupled with a loss of the channel protein in the epithelium and a gain of Cx26 in the stromal compartment suggests that the presence of lesions changes the uterine environment and thereby the differentiation programme. This aberrant expression of connexins may be an additional factor that contributes to endometriosis-associated infertility.</p>
]]></description>
<dc:creator><![CDATA[Winterhager, E., Grummer, R., Mavrogianis, P.A., Jones, C.J.P., Hastings, J.M., Fazleabas, A.T.]]></dc:creator>
<dc:date>Tue, 15 Sep 2009 08:16:32 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap060</dc:identifier>
<dc:title><![CDATA[Connexin expression pattern in the endometrium of baboons is influenced by hormonal changes and the presence of endometriotic lesions]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>652</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>645</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/10/653?rss=1">
<title><![CDATA[Endometriotic stromal cells lose the ability to regulate cell-survival signaling in endometrial epithelial cells in vitro]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/10/653?rss=1</link>
<description><![CDATA[
<p>In normal endometrium, stromal factors regulate the growth of epithelial cells. However, epithelial cells in endometriotic lesions display increased proliferation and decreased apoptosis. This work tested the hypothesis that in endometriosis stromal cells lose the ability to regulate survival signaling and cell growth in epithelial cells. Primary normal, endometriotic eutopic and ectopic epithelial cells were cultured in the presence of medium conditioned by normal, eutopic and ectopic endometriotic endometrial stromal cells. Endometriotic epithelial cells showed higher Survivin expression than normal epithelial cells. Conditioned medium (CM) from normal or eutopic endometriotic stromal cells significantly inhibited the Survivin expression and AKt phosphorylation in normal or eutopic endometriotic epithelial cells. However, CM from ectopic endometriotic stromal cells did not have an inhibitory effect on normal or ectopic endometriotic epithelial cells. Inhibition of AKt phosphorylation and Survivin expression in normal or eutopic endometriotic epithelial cells in the presence of stromal factors from normal or eutopic endometriotic stromal cells was enhanced by progesterone, whereas progesterone had little effect in the presence of stromal factors from ectopic endometriotic stromal cells. The inability of ectopic endometriotic stromal cells to regulated PI3K/AKt/Survivin signaling and mediate the progesterone response in endometriotic epithelial cells may facilitate epithelial cell proliferation in endometriosis and promote the survival of endometriotic lesions.</p>
]]></description>
<dc:creator><![CDATA[Zhang, H., Li, M., Zheng, X., Sun, Y., Wen, Z., Zhao, X.]]></dc:creator>
<dc:date>Tue, 15 Sep 2009 08:16:33 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap069</dc:identifier>
<dc:title><![CDATA[Endometriotic stromal cells lose the ability to regulate cell-survival signaling in endometrial epithelial cells in vitro]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>663</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>653</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/10/665?rss=1">
<title><![CDATA[Induction of endometrial epithelial cell invasion and c-fms expression by transforming growth factor beta]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/10/665?rss=1</link>
<description><![CDATA[
<p>Transforming growth factor beta 1 (TGF-&beta;1) levels are increased in the peritoneal fluid of endometriosis patients, and endometrial cells express TGF-&beta; signaling components; however, little is known regarding the role of TGF-&beta; in endometriosis. Our objective was to examine the effects of TGF-&beta;1 on (i) the expression of macrophage colony-stimulating factor receptor encoded by the <I>c-fms</I> gene, (ii) transmesothelial invasiveness of endometrial cells, (iii) cellular proliferation and (iv) attachment to peritoneal mesothelial cells (PMCs). Effects of TGF-&beta;1 on <I>c-fms</I> mRNA expression were determined by real-time RT&ndash;PCR and c-fms cell-surface expression by flow cytometry. Effects of TGF-&beta;1 on the invasiveness of the immortalized endometrial epithelial cell (EEC) line EM42 and primary EECs were examined using a three-dimensional <I>in vitro</I> system modeling the peritoneum. Cellular proliferation and attachment to PMCs were also examined using established techniques. TGF-&beta;1 had little or no effect on cellular proliferation and endometrial cell attachment to PMCs. TGF-&beta;1 significantly induced the expression of <I>c-fms</I> mRNA and c-fms cell-surface expression. TGF-&beta;1 enhanced transmesothelial invasion by EM42 cells and EECs. Antagonists of TGF-&beta;1 signaling significantly inhibited both the induction of <I>c-fms</I> expression and cellular invasiveness, suggesting that additional studies are warranted to assess the therapeutic potential of TGF-&beta; antagonists in endometriosis.</p>
]]></description>
<dc:creator><![CDATA[Liu, Y.-g., Tekmal, R. R., Binkley, P. A., Nair, H. B., Schenken, R. S., Kirma, N. B.]]></dc:creator>
<dc:date>Tue, 15 Sep 2009 08:16:33 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap043</dc:identifier>
<dc:title><![CDATA[Induction of endometrial epithelial cell invasion and c-fms expression by transforming growth factor beta]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>673</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>665</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/10/675?rss=1">
<title><![CDATA[Differential actions of estrogen and SERMs in regulation of the actin cytoskeleton of endometrial cells]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/10/675?rss=1</link>
<description><![CDATA[
<p>Estrogen and selective estrogen receptor modulators (SERMs) differentially impact endometrial cell function, however, the biological basis of these differences is not established. Deregulated cell adhesion to the extracellular matrix, cell movement and invasion are related to endometrial disorders, such as endometriosis or endometrial cancer. Remodeling of the actin cytoskeleton is required to achieve cell adhesion and movement. Estrogen receptor (ER) regulates actin and cell membrane remodeling through extra-nuclear signaling cascades. In this article, we show that administration of 17&beta;-estradiol (E2) and tamoxifen (TAM) to immortalized Ishikawa endometrial cells or to human endometrial stromal cells (ESC) results in remodeling of actin fibers and cell membrane. This is linked to rapid phosphorylation on Thr<sup>558</sup> of the actin-binding protein moesin and enhanced migration and invasion of normal and Ishikawa cells. Raloxifene (RAL) does not result in moesin activation or actin remodeling. When endometrial cells are exposed to E2 in the presence of TAM or RAL, both SERMs interfere with the recruitment of moesin, with the remodeling of the cytoskeleton, and with cell movement and migration induced by E2. The differential actions of E2, TAM and RAL are linked to a distinct modulation of the extra-nuclear signaling of ER to G proteins and to the Rho-associated kinase. These findings increase our understanding of the actions of estrogen and SERMs in endometrial cells and highlight potential molecular targets to interfere with the estrogen-related altered cell adhesion encountered in endometrial disorders.</p>
]]></description>
<dc:creator><![CDATA[Flamini, M.I., Sanchez, A.M., Goglia, L., Tosi, V., Genazzani, A.R., Simoncini, T.]]></dc:creator>
<dc:date>Tue, 15 Sep 2009 08:16:33 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap045</dc:identifier>
<dc:title><![CDATA[Differential actions of estrogen and SERMs in regulation of the actin cytoskeleton of endometrial cells]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>685</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>675</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/10/687?rss=1">
<title><![CDATA[Peroxisome-proliferator activator receptor-gamma activation decreases attachment of endometrial cells to peritoneal mesothelial cells in an in vitro model of the early endometriotic lesion]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/10/687?rss=1</link>
<description><![CDATA[
<p>The aim of this study was to investigate whether peroxisome proliferator-activated receptor (PPAR)- activation has an effect on the attachment of endometrial cells to peritoneal mesothelial cells in a well-established <I>in vitro</I> model of the early endometriotic lesion. The endometrial epithelial cell line EM42 and mesothelial cell line LP9 were used for this study. EM42 cells, LP9 cells or both were treated with the PPAR- agonist ciglitazone (CTZ) at varying concentrations (10, 20 and 40 &micro;M) <FONT FACE="arial,helvetica">x</FONT> 48 h with subsequent co-culture of EM42 and LP9 cells. The rate of EM42 attachment and invasion through LP9 cells was then assessed and compared with control (EM42 and LP9 cells co-cultured without prior treatment with CTZ). Next, attachment of CTZ-treated and untreated EM42 cells to hyaluronic acid (HA), a cell adhesion molecule (CAM) on peritoneal mesothelial cells, were assessed. Although there was no difference in EM42 attachment when LP9 cells alone were treated with CTZ, treatment of EM42 cells with 40 &micro;M CTZ decreased EM42 attachment to LP9 cells by 27% (<I>P</I> &lt; 0.01). Treatment of both EM42 and LP9 cells with 40 &micro;M CTZ decreased EM42 attachment to LP9 by 37% (<I>P</I> &lt; 0.01). Treatment of EM42 cells with 40 &micro;M CTZ decreased attachment to HA by 66% (<I>P</I> = 0.056). CTZ did not decrease invasion of EM42 cells through the LP9 monolayer. CTZ may inhibit EM42 cell proliferation. In conclusion, CTZ significantly decreased EM42 attachment to LP9 cells and HA in an <I>in vitro</I> model of the early endometriotic lesion.</p>
]]></description>
<dc:creator><![CDATA[Kavoussi, S.K., Witz, C.A., Binkley, P.A., Nair, A.S., Lebovic, D.I.]]></dc:creator>
<dc:date>Tue, 15 Sep 2009 08:16:33 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap061</dc:identifier>
<dc:title><![CDATA[Peroxisome-proliferator activator receptor-gamma activation decreases attachment of endometrial cells to peritoneal mesothelial cells in an in vitro model of the early endometriotic lesion]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>692</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>687</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://molehr.oxfordjournals.org/cgi/content/short/15/10/693?rss=1">
<title><![CDATA[Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression]]></title>
<link>http://molehr.oxfordjournals.org/cgi/content/short/15/10/693?rss=1</link>
<description><![CDATA[
<p>Dienogest is a specific progesterone receptor agonist with potent oral endometrial activity and is used in the treatment of endometriosis. In this study, we examined the direct effects of dienogest on the proliferation of human endometrial epithelial cells using an immortalized cell line. 5-Bromo-2'-deoxyuridine incorporation into the cells was inhibited by dienogest and by progesterone (P<SUB>4</SUB>) in dose-dependent fashion at concentrations of 10<sup>&ndash;8</sup> mol/l or higher. To identify the target genes of dienogest and P<SUB>4</SUB>, we screened the expression of 84 genes related to cell cycle regulation by real-time polymerase chain reaction after 6 h of treatment at a concentration of 10<sup>&ndash;7</sup> mol/l. Results showed that only cyclin D1 expression was significantly down-regulated, although expression of the other genes did not significantly change after dienogest or P<SUB>4</SUB> treatment compared with the control. In a time-course study during the first 24 h after drug treatment, dienogest and P<SUB>4</SUB> each produced a lasting decrease in the expression of cyclin D1 mRNA, followed by a decrease in cyclin E1 mRNA but not an increase in the expression of cell cycle inhibitor genes (p21, p27 and p53). These findings suggest that dienogest directly inhibits the proliferation of human endometrial epithelial cells with suppression of cyclin D1 gene expression.</p>
]]></description>
<dc:creator><![CDATA[Shimizu, Y., Takeuchi, T., Mita, S., Mizuguchi, K., Kiyono, T., Inoue, M., Kyo, S.]]></dc:creator>
<dc:date>Tue, 15 Sep 2009 08:16:33 PDT</dc:date>
<dc:identifier>info:doi/10.1093/molehr/gap042</dc:identifier>
<dc:title><![CDATA[Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>15</prism:volume>
<prism:endingPage>701</prism:endingPage>
<prism:publicationDate>2009-10-01</prism:publicationDate>
<prism:startingPage>693</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

</rdf:RDF>